DK0839132T5 - Fremgangsmåde til fremstilling af amorft [R-(R*,R*)]-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyrecalciumsalt (2:1) - Google Patents

Fremgangsmåde til fremstilling af amorft [R-(R*,R*)]-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyrecalciumsalt (2:1)

Info

Publication number
DK0839132T5
DK0839132T5 DK96924553T DK96924553T DK0839132T5 DK 0839132 T5 DK0839132 T5 DK 0839132T5 DK 96924553 T DK96924553 T DK 96924553T DK 96924553 T DK96924553 T DK 96924553T DK 0839132 T5 DK0839132 T5 DK 0839132T5
Authority
DK
Denmark
Prior art keywords
phenylamino
methylethyl
fluorophenyl
pyrrole
dihydroxy
Prior art date
Application number
DK96924553T
Other languages
Danish (da)
English (en)
Other versions
DK0839132T3 (da
Inventor
Dieter Schweiss
Min Lin
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21696097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0839132(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of DK0839132T3 publication Critical patent/DK0839132T3/da
Application granted granted Critical
Publication of DK0839132T5 publication Critical patent/DK0839132T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
DK96924553T 1995-07-17 1996-07-16 Fremgangsmåde til fremstilling af amorft [R-(R*,R*)]-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyrecalciumsalt (2:1) DK0839132T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US145395P 1995-07-17 1995-07-17
PCT/US1996/011807 WO1997003960A1 (en) 1995-07-17 1996-07-16 NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS [R-(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1)

Publications (2)

Publication Number Publication Date
DK0839132T3 DK0839132T3 (da) 2001-04-09
DK0839132T5 true DK0839132T5 (da) 2006-03-20

Family

ID=21696097

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96924553T DK0839132T5 (da) 1995-07-17 1996-07-16 Fremgangsmåde til fremstilling af amorft [R-(R*,R*)]-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyrecalciumsalt (2:1)

Country Status (37)

Country Link
US (1) US6274740B1 (enExample)
EP (1) EP0839132B1 (enExample)
JP (1) JP4064459B2 (enExample)
KR (1) KR100400805B1 (enExample)
CN (1) CN1087289C (enExample)
AR (1) AR002849A1 (enExample)
AT (1) ATE199542T1 (enExample)
AU (1) AU700794B2 (enExample)
BG (1) BG63631B1 (enExample)
BR (1) BR9609714A (enExample)
CA (1) CA2220455C (enExample)
CO (1) CO4700441A1 (enExample)
CZ (1) CZ289421B6 (enExample)
DE (1) DE69611999T2 (enExample)
DK (1) DK0839132T5 (enExample)
EA (1) EA000625B1 (enExample)
EE (1) EE03605B1 (enExample)
ES (1) ES2156997T3 (enExample)
GE (1) GEP20002027B (enExample)
GR (1) GR3035859T3 (enExample)
HR (1) HRP960312B1 (enExample)
HU (1) HU220343B (enExample)
IL (1) IL122161A (enExample)
IN (1) IN185276B (enExample)
MX (1) MX9708959A (enExample)
NO (1) NO309322B1 (enExample)
NZ (1) NZ313008A (enExample)
PE (1) PE1698A1 (enExample)
PL (1) PL191017B1 (enExample)
PT (1) PT839132E (enExample)
RO (1) RO120069B1 (enExample)
SI (1) SI0839132T1 (enExample)
SK (1) SK283204B6 (enExample)
UA (1) UA50743C2 (enExample)
UY (1) UY24286A1 (enExample)
WO (1) WO1997003960A1 (enExample)
ZA (1) ZA966043B (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
IN191236B (enExample) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
US6646133B1 (en) 2000-10-17 2003-11-11 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
HU226640B1 (en) * 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
IL155890A0 (en) * 2000-11-16 2003-12-23 Teva Pharma HYDROLYSIS OF [R(R*,R*)]-2-(4-FLUOROPHENYL)-beta,delta-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
KR100790766B1 (ko) 2000-12-27 2008-01-03 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴의 결정 형태, 이의 제조방법 및 이를 포함하는 약제학적 조성물
WO2002057228A1 (en) * 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) * 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (enExample) * 2001-04-11 2003-08-09 Cadila Heathcare Ltd
EP1423364B1 (en) 2001-06-29 2015-11-04 Warner-Lambert Company LLC Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
US7361772B2 (en) 2001-08-16 2008-04-22 Biocon Limited Process for the production of atorvastatin calcium
WO2003018547A2 (en) 2001-08-31 2003-03-06 Morepen Laboratories Ltd. An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CZ296967B6 (cs) * 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
BR0215644A (pt) * 2002-03-18 2004-12-21 Biocon Ltd Inibidores de redutase de hmg-coa amorfos do tamanho de partìcula desejado
RU2309141C2 (ru) * 2002-03-18 2007-10-27 Байокон Лимитид АМОРФНЫЕ ИНГИБИТОРЫ ГМГ-КоА-РЕДУКТАЗЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
AU2002356423A1 (en) * 2002-05-28 2003-12-12 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
US7179942B2 (en) 2002-07-05 2007-02-20 Bicon Limited Halo-substituted active methylene compounds
EP1562583A1 (en) * 2002-09-03 2005-08-17 Morepen Laboratories Ltd. Atorvastatin calcium form vi or hydrates thereof
US8367848B2 (en) 2003-04-11 2013-02-05 Lek Pharmaceuticals D.D. Process for the preparation of amorphous calcium salt of atorvastatin
WO2004094343A1 (en) 2003-04-22 2004-11-04 Biocon Limited NOVEL PROCESS FOR STEREOSELECTIVE REDUCTION OF ß-KETOESTERS
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7557238B2 (en) 2003-09-18 2009-07-07 Biocon Limited Process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
CZ298382B6 (cs) * 2004-03-10 2007-09-12 Zentiva, A. S. Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace
SI1727795T1 (sl) * 2004-03-17 2012-05-31 Ranbaxy Lab Ltd Postopek za pripravo atorvastatin kalcija v amorfni obliki
EP1745020A2 (en) 2004-05-05 2007-01-24 Pfizer Products Incorporated Salt forms of atorvastatin
RU2412191C2 (ru) * 2004-07-16 2011-02-20 Лек Фармасьютиклз Д.Д. Продукты окислительной деструкции кальций аторвастатина
JP2008510798A (ja) 2004-08-27 2008-04-10 バイオコン・リミテッド 非晶質アトルバスタチンカルシウムのための方法
JP2008514722A (ja) * 2004-09-30 2008-05-08 ドクター レディズ ラボラトリーズ リミテッド 非結晶性アトルバスタチンカルシウム
MX2007004425A (es) * 2004-10-18 2007-06-07 Teva Pharma Proceso para preparar hemi-calcio de atorvastatina amorfo disolviendo la sal en un solvente organico que es una mezcla de un alcohol y una cetona y/o un ester y removiendo el solvente.
KR20070067175A (ko) * 2004-10-28 2007-06-27 워너-램버트 캄파니 엘엘씨 무정형 아토르바스타틴 형성 방법
CA2588216A1 (en) 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
JP2008521878A (ja) * 2004-12-02 2008-06-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 非晶質アトルバスタチンの医薬組成物及びその製造のための方法
US20080108664A1 (en) * 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
EP1877375A1 (en) * 2006-03-01 2008-01-16 Teva Pharmaceutical Industries Ltd Process for preparing a crystalline form of atorvastatin hemi-calcium
US20100113802A1 (en) * 2006-11-02 2010-05-06 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate
US7834195B2 (en) 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
EP2185527A2 (en) * 2007-07-11 2010-05-19 Actavis Group PTC EHF Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
US20090124817A1 (en) * 2007-11-09 2009-05-14 The Industry & Academic Cooperation In Chungnam National University Process for Preparing Amorphous Atorvastatin Calcium Nanoparticles
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
WO2010066846A2 (en) * 2008-12-11 2010-06-17 Dsm Ip Assets B.V. Method for the isolation of atorvastatin
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
SI2373609T1 (sl) 2008-12-19 2013-12-31 Krka, D.D., Novo Mesto Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
DE69634054T2 (de) 1995-07-17 2005-12-08 Warner-Lambert Co. Kristalline (R-(R*, R*))-2-(4-Fluorophenyl)-β, δ-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-((Phenylamino)Carbonyl)-1H-Pyrrol-1-Heptancarbonsäure Hemi Calcium Salz (Atorvastatin)

Also Published As

Publication number Publication date
IN185276B (enExample) 2000-12-16
AR002849A1 (es) 1998-04-29
DK0839132T3 (da) 2001-04-09
BR9609714A (pt) 1999-02-23
CZ12298A3 (cs) 1998-12-16
CA2220455C (en) 2002-09-24
EA199800128A1 (ru) 1998-08-27
PE1698A1 (es) 1998-02-19
SK283204B6 (sk) 2003-03-04
NO980209D0 (no) 1998-01-16
NO980209L (no) 1998-01-16
EP0839132B1 (en) 2001-03-07
AU700794B2 (en) 1999-01-14
ZA966043B (en) 1997-02-03
BG102188A (en) 1998-08-31
CO4700441A1 (es) 1998-12-29
CN1087289C (zh) 2002-07-10
WO1997003960A1 (en) 1997-02-06
CN1190956A (zh) 1998-08-19
ATE199542T1 (de) 2001-03-15
UA50743C2 (uk) 2002-11-15
PL324463A1 (en) 1998-05-25
IL122161A0 (en) 1998-04-05
PT839132E (pt) 2001-06-29
EE03605B1 (et) 2002-02-15
GR3035859T3 (en) 2001-08-31
JPH11510486A (ja) 1999-09-14
HU220343B (hu) 2001-12-28
HRP960312B1 (en) 2001-10-31
CZ289421B6 (cs) 2002-01-16
EP0839132A1 (en) 1998-05-06
HK1018054A1 (en) 1999-12-10
DE69611999D1 (de) 2001-04-12
EA000625B1 (ru) 1999-12-29
UY24286A1 (es) 1997-01-17
HUP9903017A3 (en) 2001-01-29
CA2220455A1 (en) 1997-02-06
KR19990029045A (ko) 1999-04-15
ES2156997T3 (es) 2001-08-01
NO309322B1 (no) 2001-01-15
NZ313008A (en) 2000-01-28
DE69611999T2 (de) 2001-07-26
MX9708959A (es) 1998-03-31
HRP960312A2 (en) 1998-02-28
IL122161A (en) 1999-07-14
SK5898A3 (en) 1998-08-05
KR100400805B1 (ko) 2003-12-24
SI0839132T1 (enExample) 2001-06-30
PL191017B1 (pl) 2006-03-31
BG63631B1 (bg) 2002-07-31
RO120069B1 (ro) 2005-08-30
AU6497896A (en) 1997-02-18
GEP20002027B (en) 2000-04-10
US6274740B1 (en) 2001-08-14
EE9700369A (et) 1998-06-15
JP4064459B2 (ja) 2008-03-19

Similar Documents

Publication Publication Date Title
DK0839132T5 (da) Fremgangsmåde til fremstilling af amorft [R-(R*,R*)]-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyrecalciumsalt (2:1)
DK0848705T3 (da) Krystallinsk [R-(R*,R*)]-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1- heptansyre-hemicalciumsalt (atorvastatin)
IL158790A0 (en) Crystalline forms of [r-(*,r*)]-2-(4-fluorophenyl) -beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
ATE207465T1 (de) Kristalline form iii des hemi calcium salzes von (r-(r*,r*))-2-(4-fluorphenyl)-beta-delta- dihydroxy-5-(1-methylethyl)-3-phenyl-4- ((phenylamino)carbonyl)-1h-pyrrol-1-heptansäure (atorvastatin)
WO2003050085A8 (en) CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-HEPTANOIC ACID CALCIUM SALT (2:1)
DE69616358D1 (de) Kristalline form iii des hemi calcium salzes von [r-(r*,r*)]-2-(4-fluorphenyl)-beta-delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrol-1-heptansäure (atorvastatin)
NZ507836A (en) Crystalline [r*(r* ,r*)]-2-(4-flurophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)